CN115698270A - 一种通过iPS细胞生产再生T细胞的方法 - Google Patents

一种通过iPS细胞生产再生T细胞的方法 Download PDF

Info

Publication number
CN115698270A
CN115698270A CN202180038576.5A CN202180038576A CN115698270A CN 115698270 A CN115698270 A CN 115698270A CN 202180038576 A CN202180038576 A CN 202180038576A CN 115698270 A CN115698270 A CN 115698270A
Authority
CN
China
Prior art keywords
cells
ips
cell
immature
hematopoietic stem
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180038576.5A
Other languages
English (en)
Chinese (zh)
Inventor
金子新
五之坪良辅
大泽光次郎
等泰道
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thyas Co ltd
Original Assignee
Thyas Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thyas Co ltd filed Critical Thyas Co ltd
Publication of CN115698270A publication Critical patent/CN115698270A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4201—Neoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4242—Transcription factors, e.g. SOX or c-MYC
    • A61K40/4243—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4261—Proteoglycans, e.g. glypican, brevican or CSPG4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18811—Sendai virus
    • C12N2760/18841—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18843—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/90—Vectors containing a transposable element

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202180038576.5A 2020-09-18 2021-09-17 一种通过iPS细胞生产再生T细胞的方法 Pending CN115698270A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2020156848 2020-09-18
JP2020-156848 2020-09-18
JP2021-070531 2021-04-19
JP2021070531 2021-04-19
PCT/JP2021/034333 WO2022059780A1 (ja) 2020-09-18 2021-09-17 ｉＰＳ細胞を介する再生Ｔ細胞の製造方法

Publications (1)

Publication Number Publication Date
CN115698270A true CN115698270A (zh) 2023-02-03

Family

ID=80776150

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180038576.5A Pending CN115698270A (zh) 2020-09-18 2021-09-17 一种通过iPS细胞生产再生T细胞的方法

Country Status (5)

Country Link
US (1) US20230183645A1 (https=)
EP (1) EP4215604A4 (https=)
JP (1) JPWO2022059780A1 (https=)
CN (1) CN115698270A (https=)
WO (1) WO2022059780A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202020145A (zh) * 2018-07-13 2020-06-01 國立大學法人京都大學 γδＴ細胞的製造方法
AU2022259170A1 (en) * 2021-04-16 2023-10-12 Thyas Co. Ltd. Cell bank composed of ips cells for introducing t cell receptor gene
WO2023249071A1 (ja) * 2022-06-24 2023-12-28 国立研究開発法人国立がん研究センター Ｔ細胞受容体

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016010154A1 (ja) * 2014-07-18 2016-01-21 宏 河本 抗原特異的ｔ細胞受容体遺伝子を有する多能性幹細胞の製造方法
CN105925535A (zh) * 2009-06-05 2016-09-07 细胞动力国际有限公司 重编程t细胞和造血细胞的方法
JP2018512380A (ja) * 2015-03-13 2018-05-17 サイズ セル セラピー コーポレイション 活性化ｔ細胞を用いるがん治療の方法
GB201911953D0 (en) * 2019-08-20 2019-10-02 Adaptimmune Ltd T cell production fram RAG inacivated iPSCs
CN111164204A (zh) * 2017-10-06 2020-05-15 赛雅思株式会社 来自iPS细胞的具有遗传多样性的T细胞群体的制备方法
CN112513256A (zh) * 2018-07-13 2021-03-16 国立大学法人京都大学 γδT细胞的制造方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2011096482A1 (ja) 2010-02-03 2013-06-13 国立大学法人 東京大学 多能性幹細胞を用いた免疫機能再建法
JP5963309B2 (ja) * 2010-11-09 2016-08-03 国立研究開発法人産業技術総合研究所 末梢血単球由来多能性幹細胞作製方法
JP6164746B2 (ja) * 2012-05-22 2017-07-19 国立大学法人 東京大学 抗原特異的ｔ細胞の製造方法
JP6715482B2 (ja) * 2014-07-18 2020-07-01 国立大学法人京都大学 多能性幹細胞から免疫細胞療法用ｔ細胞を誘導する方法
TW201835100A (zh) * 2017-02-06 2018-10-01 國立研究開發法人國立癌症研究中心 新穎ｔ細胞受體
US20200363414A1 (en) * 2017-09-05 2020-11-19 Gritstone Oncology, Inc. Neoantigen Identification for T-Cell Therapy
SG11202101789SA (en) * 2018-07-26 2021-03-30 Univ Kyoto Method for generating cells into which an exogenous antigen receptor is introduced
EP3831936A4 (en) * 2018-07-31 2022-04-13 Thyas Co. Ltd. METHOD FOR PRODUCING A REGENERATED T LYMPHOCYTE POPULATION USING IPS CELLS
CA3162755A1 (en) * 2019-11-25 2021-06-03 Kyoto University T-cell master cell bank
US20240052309A1 (en) * 2021-01-04 2024-02-15 Thyas Co. Ltd. Method for producing regenerated t cell via ips cell
AU2022259170A1 (en) * 2021-04-16 2023-10-12 Thyas Co. Ltd. Cell bank composed of ips cells for introducing t cell receptor gene

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105925535A (zh) * 2009-06-05 2016-09-07 细胞动力国际有限公司 重编程t细胞和造血细胞的方法
WO2016010154A1 (ja) * 2014-07-18 2016-01-21 宏 河本 抗原特異的ｔ細胞受容体遺伝子を有する多能性幹細胞の製造方法
JP2018512380A (ja) * 2015-03-13 2018-05-17 サイズ セル セラピー コーポレイション 活性化ｔ細胞を用いるがん治療の方法
CN111164204A (zh) * 2017-10-06 2020-05-15 赛雅思株式会社 来自iPS细胞的具有遗传多样性的T细胞群体的制备方法
CN112513256A (zh) * 2018-07-13 2021-03-16 国立大学法人京都大学 γδT细胞的制造方法
GB201911953D0 (en) * 2019-08-20 2019-10-02 Adaptimmune Ltd T cell production fram RAG inacivated iPSCs

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HARUKA WADA等: "Successful differentiation to T cells, but unsuccessful B-cell generation, from B-cell-derived induced pluripotent stem cells", INT IMMUNOL, 6 December 2010 (2010-12-06) *
彭延文等: "体外诱导小鼠胚胎干细胞分化为T淋巴细胞", 中华生物医学工程杂志, 6 November 2008 (2008-11-06) *

Also Published As

Publication number Publication date
JPWO2022059780A1 (https=) 2022-03-24
EP4215604A1 (en) 2023-07-26
WO2022059780A1 (ja) 2022-03-24
US20230183645A1 (en) 2023-06-15
EP4215604A4 (en) 2025-01-01

Similar Documents

Publication Publication Date Title
JP7778708B2 (ja) 多能性幹細胞からナチュラルキラー細胞を産生するための方法
JP5652783B2 (ja) ＮＫＴ細胞由来ｉＰＳ細胞およびそれ由来のＮＫＴ細胞
JP6715482B2 (ja) 多能性幹細胞から免疫細胞療法用ｔ細胞を誘導する方法
US20220175899A1 (en) Cytotoxic t lymphocytes specific for mutated forms of epidermal growth factor receptor for use in treating cancer
CN108289909A (zh) 用于产生工程改造的人原代血液树突细胞系的方法
CN115698270A (zh) 一种通过iPS细胞生产再生T细胞的方法
US20210238550A1 (en) METHOD FOR PRODUCING REGENERATED T CELL POPULATION VIA iPS CELLS
US20170267972A1 (en) Production method for pluripotent stem cells having antigen-specific t cell receptor gene
US20240052309A1 (en) Method for producing regenerated t cell via ips cell
US20250154458A1 (en) Methods for Making, Compositions Comprising, and Methods of Using Rejuvenated T Cells
EP4324917A1 (en) Cell bank composed of ips cells for introducing t cell receptor gene
JPWO2016010153A1 (ja) 免疫細胞療法用ｔ細胞の誘導方法
CN116744947A (zh) 一种通过iPS细胞生产再生T细胞的方法
US20220233665A1 (en) Medicinal composition
EP4355861A1 (en) Method for producing natural killer cells from pluripotent stem cells
WO2025220666A1 (en) Cytotoxic Lymphocytes Expressing Variable Region-Deleted T Cell Receptors
WO2024071411A1 (ja) ｉＰＳ細胞から誘導された免疫細胞
CN116615209A (zh) 制备再生t细胞的方法、包含再生t细胞的组合物及使用再生t细胞的方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination